Amicus Therapeutics (NASDAQ:FOLD) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.25) by 20 percent. This is a 20 percent decrease over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $78.72 million which beat the analyst consensus estimate of $77.13 million by 2.05 percent. This is a 18.54 percent increase over sales of $66.40 million the same period last year.
Why Are Entasis Therapeutics Shares Moving Higher On Thursday?
Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) stock is up sharply after the journal Nature published an article on the potential of its…
